Literature DB >> 25153237

Synthesis, biological evaluation, and docking studies of PAR2-AP-derived pseudopeptides as inhibitors of kallikrein 5 and 6.

Beatrice Severino, Ferdinando Fiorino, Angela Corvino, Giuseppe Caliendo, Vincenzo Santagada, Diego Magno Assis, Juliana R Oliveira, Luiz Juliano, Serena Manganelli, Emilio Benfenati, Francesco Frecentese, Elisa Perissutti, Maria Aparecida Juliano.   

Abstract

A series of protease activated receptor 2 activating peptide (PAR2-AP) derivatives (1-15) were designed and synthesized. The obtained compounds were tested on a panel of human kallikreins (hKLK1, hKLK2, hKLK5, hKLK6, and hKLK7) and were found completely inactive toward hKLK1, hKLK2, and hKLK7. Aiming to investigate the mode of interaction between the most interesting compounds and the selected hKLKs, docking studies were performed. The described compounds distinguish the different human tissue kallikreins with compounds 1 and 5 as the best hKLK5 and hKLK6 inhibitors, respectively.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25153237     DOI: 10.1515/hsz-2014-0190

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  2 in total

1.  PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.

Authors:  Honghai Ma; Alexandra Hockla; Christine Mehner; Matt Coban; Niv Papo; Derek C Radisky; Evette S Radisky
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

2.  Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.

Authors:  Elena De Vita; Niels Smits; Helma van den Hurk; Elizabeth M Beck; Joanne Hewitt; Gemma Baillie; Emily Russell; Andrew Pannifer; Véronique Hamon; Angus Morrison; Stuart P McElroy; Philip Jones; Natalia A Ignatenko; Nikolas Gunkel; Aubry K Miller
Journal:  ChemMedChem       Date:  2019-11-18       Impact factor: 3.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.